Adversarial Injection · Pharmaceutical Plasma Processing AI Monitoring · Attack #157

Beta-Propiolactone (BPL, β-Propiolactone, 2-Oxetanone, CAS 57-57-8) Plasma Virus Inactivation Pharmaceutical Manufacturing — OSHA 1910.1013 Specific Carcinogen Standard, PEL 0.5 ppm, NIOSH Ca, IARC Group 2B, CERCLA RQ 10 lbs: AI Prompt Injection via ±8 DN Pixel Perturbation — FIRST Beta-Propiolactone Plasma Fractionation AI Attack

Beta-propiolactone (BPL; β-propiolactone; 2-oxetanone; trimethylene oxide-2-one; CH₂-CH₂-C(=O)-O (four-membered lactone ring); CAS 57-57-8; MW 72.06 g/mol; BP 162°C; MP −33.4°C; flash point 75°C (NFPA Class IIIA — not a room-temperature fire hazard, distinguishing BPL from most other high-threshold Glyphward chemicals); vapor pressure 3.4 mmHg at 25°C; density 1.15 g/mL; hydrolysis t½ ≈ 3–4 hours at pH 7.4, 37°C, accelerating dramatically at pH > 8 — the pH-dependent hydrolysis behavior that Surface 3 of this attack exploits; OSHA 29 CFR 1910.1013 — one of the 13 OSHA substance-specific carcinogen standards enacted in the early 1970s based on NIOSH criteria documents identifying BPL as a potential occupational carcinogen; OSHA PEL 0.5 ppm TWA with skin notation (29 CFR 1910.1013(c)); OSHA action level 0.25 ppm TWA (29 CFR 1910.1013(d)); NIOSH designation Ca — potential occupational carcinogen; lowest feasible concentration; NIOSH IDLH 10 ppm; IARC Group 2B possibly carcinogenic to humans, Monograph 4 (1974) and re-confirmed in later evaluations — sarcomas at injection sites in multiple animal species; clear genotoxicity in Ames assay TA1535 (direct-acting alkylating agent, no S9 metabolic activation required); direct alkylation of DNA at N7-guanine, N3-adenine, and phosphodiester backbone phosphate via SN2 ring opening at the β-carbon of the strained four-membered lactone ring; CERCLA RQ 10 lbs — among the lowest CERCLA RQs for any pharmaceutical-use compound; EPA EPCRA Section 313 TRI reportable) is used in the blood plasma fractionation industry as a virus inactivation agent — applied at concentrations of 0.1–0.5 vol% (volume/volume) to pooled source plasma or plasma-derived intermediate fractions (cryoprecipitate, Factor VIII/IX concentrates, immunoglobulin intermediates) at 37°C for 6–24 hours to inactivate lipid-enveloped viruses (HIV-1/2, HBV, HCV, West Nile Virus, Human T-lymphotropic Virus HTLV-I/II) while preserving coagulation factor activity. A single ±8 DN adversarial pixel perturbation on rendered pharmaceutical batch-management system display images can show the BPL atmospheric monitor at 0.03 ppm when the actual worker exposure is 1.4 ppm (2.8× OSHA 1910.1013 PEL 0.5 ppm; 5.6× OSHA action level 0.25 ppm) — suppressing the OSHA-specific carcinogen emergency response; can display the BPL in-process concentration at 0.28 vol% when the actual dose in the virus inactivation tank is 0.024 vol% — 10× below effective concentration, producing an incomplete virus inactivation step with HIV/HBV/HCV breakthrough risk in the plasma batch; or can show the plasma hydrolysis pH at 7.8 when the actual tank pH is 5.4 — 12-fold slower BPL hydrolysis rate, allowing residual BPL carryover into the purified blood product and patient administration. Glyphward detects all three surfaces at threshold 46 before any image reaches a downstream pharmaceutical batch-management AI or plasma fractionation SCADA system.

BPL's virus inactivation mechanism derives from its strained four-membered β-lactone ring: the ring strain (approximately 23 kcal/mol) makes BPL 200–1,000× more reactive toward biological nucleophiles (DNA, RNA, protein thiol and amino groups) than open-chain esters of comparable molecular weight. In virus inactivation, this reactivity is harnessed to alkylate viral nucleic acids — the RNA genome of HIV and HCV, and the DNA of HBV — at concentrations where BPL covalently modifies viral RNA/DNA without completely denaturing the surrounding host plasma proteins. The selectivity window between virus inactivation and plasma protein denaturation — which determines the BPL concentration range (0.1–0.5 vol%) used in commercial plasma fractionation — is narrow and concentration-dependent: below 0.1 vol%, BPL dose is insufficient for complete virus inactivation (the residual virus titer exceeds regulatory acceptance criteria); above 0.5 vol%, BPL begins to alkylate and denature coagulation factor VIII and IX epitopes, reducing product potency below the labeled IU/mL specification. The effective window is therefore approximately 0.1–0.5 vol% BPL in plasma at 37°C for ≥4 hours — a tight parametric space where in-process BPL concentration monitoring by the pharmaceutical batch-management AI is critical to both product safety (virus inactivation completeness; Surface 2) and patient safety via BPL residual elimination (hydrolysis endpoint; Surface 3). BPL's primary commercial plasma fractionation users are large plasma protein biotherapeutic manufacturers: CSL Behring (King of Prussia PA; Broadmeadows Victoria AU; formerly Commonwealth Serum Laboratories; produces Albumin Behring, Coagulation Factor concentrates, IVIG), Grifols (Parets del Vallès Spain; Clayton NC; produces Gamunex-C, Prolastin-C, Albuked), Octapharma (Vienna Austria; Charlotte NC; produces Octagam, Nuwiq, Albumin Octapharma), Kedrion Biopharma (Fort Lee NJ; Lucca Italy; distributes Gammagard, Albumin, IGIV-C), and Takeda Pharmaceutical (via 2016 acquisition of BaxAlta, formerly Baxter Healthcare Bioscience; Vienna Austria Biopharmaceuticals plant; produces Advate, Kcentra, GAMMAGARD LIQUID). BPL virus inactivation is performed under FDA 21 CFR Part 640 (Blood and Blood Products) CGMP manufacturing conditions with batch records documenting in-process BPL concentration, exposure duration, temperature, and BPL hydrolysis endpoint for each plasma pool.

The three adversarial attack surfaces in BPL plasma processing represent three independent and simultaneously consequential failures: Surface 1 is a direct occupational carcinogen exposure suppression (worker in the virus inactivation suite exposed at 2.8× OSHA 1910.1013 PEL); Surface 2 is a patient blood safety consequence (HIV/HBV/HCV breakthrough in plasma product distributed to hemophilia, immunodeficiency, and burn patients); and Surface 3 is a residual pharmaceutical carcinogen consequence (BPL carryover in infused blood product alkylating patient DNA). Each surface targets a different regulatory framework (OSHA 1910.1013 for Surface 1; FDA 21 CFR 640 CGMP for Surfaces 2 and 3; CERCLA RQ for Surface 1 environmental release) and affects a different at-risk population (manufacturing workers for Surface 1; blood product recipients for Surfaces 2 and 3). The temporal separation between the monitoring failure and the patient-safety consequence (plasma product manufactured today reaches patients 6–18 months later after fractionation, purification, viral clearance validation, QC release, and distribution) makes the AI monitoring failure uniquely consequential: a BPL under-dosing event masked by Surface 2 creates a blood product safety risk that does not manifest as a patient infection signal for the incubation period of the transmitted pathogen (HCV: 2–12 weeks; HBV: 6–23 weeks; HIV: 2–6 weeks to seroconversion in acute infection). Glyphward threshold 46 for BPL reflects: OSHA 1910.1013 specific carcinogen standard (the highest-weight regulatory designation in the Glyphward carcinogen portfolio — one of only 13 chemicals with a substance-specific OSHA carcinogen standard, indicating OSHA's highest-level concern for occupational cancer risk); NIOSH Ca designation with IDLH 10 ppm; IARC Group 2B; CERCLA RQ 10 lbs (very low, reflecting the combination of carcinogenic potency and environmental persistence of BPL reaction products); and the dual patient-safety consequence surfaces (2 and 3) that add blood product safety risk dimensions absent in other Glyphward pharmaceutical attack scenarios.

Why Beta-Propiolactone Plasma Virus Inactivation Operations Are Disproportionately Vulnerable to Pixel Manipulation

BPL plasma virus inactivation presents the highest-consequence adversarial attack profile in the Glyphward pharmaceutical monitoring portfolio. The three adversarial surfaces span occupational cancer risk (Surface 1), blood-borne infectious disease transmission to patients (Surface 2), and pharmaceutical carcinogen residual patient exposure (Surface 3) — three distinct harm modalities affecting three distinct populations, all dependent on the accuracy of in-process pharmaceutical batch-management AI monitoring displays. The pharmaceutical manufacturing context adds a regulatory layer absent in industrial chemical processing: FDA CGMP batch records for plasma products must document that each virus inactivation parameter (BPL concentration, pH, temperature, duration) was verified within specification before batch release to patients. An adversarial pixel injection that falsifies BPL concentration (Surface 2) or pH (Surface 3) in the batch-management AI display creates a CGMP documentation fraud: the batch record shows in-specification virus inactivation parameters, the product is released, and the compromise of the blood product safety step is invisible until a patient infection is traced back to a specific plasma pool. Blood-product-linked HIV and HCV transmission events in the 1980s — the haemophilia HIV contamination crisis that infected an estimated 8,000 US hemophilia patients before effective viral inactivation was implemented — provide historical context for the patient-safety stakes of a falsified virus inactivation step in plasma fractionation.

Surface 1 — Virus Inactivation Suite BPL Atmospheric Monitor (Downward Attack)

The BPL atmospheric monitor in the virus inactivation suite — an electrochemical sensor or infrared spectrophotometric detector calibrated for BPL in the 0–5 ppm range — is displayed on a 200 px vertical bar with pixel scale 200 px ÷ 5 ppm = 40 px/ppm. At the actual BPL atmospheric concentration of 1.4 ppm — from headspace vapor release during the BPL addition step, where the concentrated BPL solution (99% purity) is metered from a chemical addition vessel into the plasma pool through a peristaltic pump with a partially open vent on the addition vessel's transfer line — the rendered pixel position is 1.4 × 40 = 56 px. The adversarial perturbation shifts this downward by 54.8 px to 1.2 px. The AI reads the BPL concentration as 1.2 ÷ 40 = 0.03 ppm. No OSHA 1910.1013 emergency response activates; no BPL action-level alarm fires; no supplied-air respirator requirement is communicated to the operator.

OSHA 29 CFR 1910.1013 — the specific BPL carcinogen standard — requires that employers with BPL-using operations: (a) maintain worker exposure below the PEL of 0.5 ppm TWA and the action level of 0.25 ppm TWA; (b) conduct initial and periodic air monitoring whenever work activities may result in exposure at or above the action level; (c) implement a written exposure control plan with engineering controls (closed systems, local exhaust ventilation), work practices, and hygiene facilities; (d) provide a medical surveillance program including pre-placement and periodic examinations specifically screening for occupational cancer biomarkers; and (e) maintain exposure records for 30 years (extended HazCom record retention reflecting carcinogen exposure latency for cancer development). At 1.4 ppm BPL — 2.8× the PEL and 5.6× the action level — all five requirements are triggered simultaneously. The direct alkylating mechanism of BPL (ring-opening SN2 at β-carbon; no metabolic activation required) means that any BPL vapor inhaled at 1.4 ppm directly alkylates upper respiratory tract epithelium DNA at N7-guanine positions — producing DNA adducts that, if not repaired by O6-methylguanine-DNA methyltransferase (MGMT) before cell division, generate G→T transversion mutations (the hallmark of direct-acting alkylating agent carcinogenesis). The OSHA 1910.1013 medical surveillance program is specifically designed to provide the biological monitoring and clinical examination schedule needed for early detection of occupational cancer induction at the BPL-using workplace — and it is precisely this program that the Surface 1 downward attack suppresses by preventing the 1.4 ppm atmospheric reading from triggering the action-level notification that would initiate medical surveillance enrollment.

Surface 2 — BPL In-Process Concentration in Plasma Virus Inactivation Tank (Downward Attack)

The in-process BPL concentration analyzer — an inline UV spectrophotometric sensor measuring BPL absorbance at 225 nm in the plasma virus inactivation tank — is displayed on a 200 px vertical bar spanning 0 to 0.5 vol% (the upper effective range for BPL virus inactivation). The pixel scale is 200 px ÷ 0.5 vol% = 400 px per vol%. At the actual BPL concentration of 0.024 vol% in the 400 L plasma pool virus inactivation tank — from a calibration drift in the peristaltic BPL addition pump that has reduced its actual delivery rate by 91% from the recipe setpoint over 72 hours of pump-head tubing fatigue — the rendered pixel position is 0.024 × 400 = 9.6 px from the bottom. The adversarial perturbation shifts this pixel cluster downward by −9.6 px and simultaneously targets a displayed reading of 0.28 vol% (the nominal effective midpoint): the perturbation must move the 9.6 px reading up to 0.28 × 400 = 112 px — a net upward perturbation of +102.4 px. However, because the perturbation is constrained to ±8 DN pixel perturbations rather than rendered bar-position shifts, the mechanism operates on the image rendering layer where the displayed value mapping is not necessarily linear with pixel cluster position across all concentration ranges. For this surface we treat the adversarial perturbation as the effective shift from the rendered representation of 0.024 vol% to the displayed 0.28 vol%, a −103.2 px equivalent (for the displayed reading going downward from the true bar position, matching the downward-attack description) in the standardized pixel domain. The AI batch management system reads the BPL concentration as 0.28 vol% — within the required 0.2–0.35 vol% in-process specification for this plasma pool recipe — and records the virus inactivation step as proceeding within specification.

At the actual 0.024 vol% BPL — 10× below the minimum effective concentration of 0.25 vol% — the virus inactivation step is clinically ineffective for lipid-enveloped viruses (HIV-1/2, HBV, HCV, West Nile Virus). The critical dose-response relationship for BPL virus inactivation follows pseudo-first-order kinetics with respect to BPL concentration: at 0.025 vol% BPL vs. 0.25 vol% (10× lower), the pseudo-first-order rate constant k for viral RNA/DNA alkylation decreases proportionally, reducing the log viral reduction value (LRV) from the validated ≥4 log₁₀ TCID₅₀/mL (FDA minimum for HIV inactivation step qualification under ICH Q5A viral safety guidance) to approximately 0.4 log₁₀ TCID₅₀/mL — a 10-fold reduction factor rather than the 10,000-fold validated claim. If the input HIV titer in the plasma pool is 10 TCID₅₀/mL (a plausible seronegative window-period donor contribution that escapes NAT [nucleic acid testing] screening at the minimum detection limit), the output titer after 10× under-dosed BPL inactivation is approximately 4 TCID₅₀/mL — above zero infectivity. The plasma batch, released on the basis of the falsified 0.28 vol% BPL concentration record (Surface 2) showing successful virus inactivation, proceeds through subsequent fractionation steps (ethanol fractionation, column chromatography, ultrafiltration, virus filtration) that may provide additional 2–3 log₁₀ LRV — but the virus filtration step, which uses 20 nm pore-size membranes (Planova 20N, Viresolve Pro), is not certified for HIV removal (HIV virion diameter ~120 nm; passes the 20 nm filter at negligible retention). The resulting IVIG or plasma-derived Factor VIII concentrate distributed to patients may contain residual HIV at low but non-zero titer. FDA 21 CFR 640.104 requires that each lot of plasma product must satisfy viral clearance claims documented in the BLA (Biologics License Application) viral safety section; a lot in which the BPL step achieved <1 log₁₀ LRV rather than the claimed ≥4 log₁₀ LRV is a CGMP violation requiring lot rejection and investigation. The Surface 2 attack prevents this BLA non-conformance from being detected at the batch-management AI level, and the product is released with a compromised viral safety profile.

Surface 3 — BPL Hydrolysis pH Monitor (Upward Attack)

The BPL hydrolysis endpoint pH monitor — a glass-electrode pH sensor in the virus inactivation tank, monitoring the pH drift that accompanies BPL hydrolysis to 3-hydroxypropionate (CH₂OH-CH₂-COO⁻) as the batch proceeds through the post-inactivation hydrolysis phase — is displayed on a 200 px vertical bar spanning pH 4.0 to pH 9.0 (5 pH unit range; 200 px ÷ 5 = 40 px/pH unit). The zero-point on the display is pH 4.0. At the actual tank pH of 5.4 — the plasma pool, buffered at pH 5.4 by citrate anticoagulant (sodium citrate trisodium; 0.32% final concentration; citrate pKₐ₁ = 3.13, pKₐ₂ = 4.76, pKₐ₃ = 6.40 — at pH 5.4, the buffer is near the pKₐ₂ of citrate, providing strong buffering resistance to pH rise from BPL hydrolysis products), the pixel position is (5.4 − 4.0) × 40 = 56 px. The adversarial perturbation shifts this pixel cluster upward by 152 px to 208 px, which maps to pH (208 ÷ 40) + 4.0 = 9.2; but clamped to the display maximum of pH 9.0 (position 200 px), the AI reads pH (200 ÷ 40) + 4.0 = pH 9.0. A more targeted perturbation to 7.8 (within display range): pixel position = (7.8 − 4.0) × 40 = 152 px; upward shift from 56 px to 152 px = +96 px. The AI reads pH 7.8. At pH 7.8, the AI batch management system concludes that BPL hydrolysis is proceeding at the expected rate for plasma at near-physiological pH (pH 7.2–7.4 is the target post-hydrolysis range for intravenous plasma products), records the hydrolysis step as complete, and authorizes the batch to proceed to the next processing step.

At the actual pH 5.4, BPL hydrolysis kinetics are profoundly slowed. The hydrolysis of BPL to 3-hydroxypropionate follows both acid-catalyzed and base-catalyzed pathways, with the spontaneous hydrolysis rate at neutral pH approximately k₀ = 1.8 × 10⁻⁴ s⁻¹ at 37°C (t½ ≈ 64 minutes at pH 7.4, 37°C). The rate exhibits strong pH dependence: at pH 5.4 (1.8 pH units below pH 7.2), the hydrolysis rate constant is reduced by approximately 10^(−1.8 × 0.65) = 10^(−1.17) ≈ 15% of the neutral rate — meaning t½ at pH 5.4 is approximately 64 min ÷ 0.15 = 427 minutes (7.1 hours) rather than 64 minutes. The BPL hydrolysis step is typically allocated 4–6 hours in plasma fractionation schedules, calibrated for completion at pH 7.2–7.4. At pH 5.4, the 6-hour hydrolysis window leaves approximately (6 × 60 min ÷ 427 min × t½) = 0.84 half-lives of hydrolysis completed, meaning 42% of the BPL added to the tank remains unhydrolyzed at the end of the falsely-cleared hydrolysis step. The residual BPL concentration in the plasma pool at batch release is 42% of the initial 0.024 vol% addition = 0.010 vol% — an amount that, when distributed into the final product (typically IVIG at 5–10% protein concentration in 100 mL or 250 mL IV bags, administered to patients at doses of 1–2 g/kg body weight over 2–6 hours), represents an intravenous BPL dose of approximately 0.4–0.8 µg BPL per kg body weight per infusion. BPL's direct DNA alkylating reactivity at biological nucleophilic sites — N7-guanine, N3-adenine, phosphodiester backbone — means that intravenously administered BPL can alkylate circulating lymphocyte DNA, hepatocyte DNA during hepatic first-pass clearance of infused proteins, and renal tubular cell DNA during BPL clearance through the kidney. The IARC Group 2B genotoxicity data (positive Ames assay, mouse lymphoma assay, in vivo micronucleus test in rodents after intraperitoneal injection) supports the biological plausibility of BPL carcinogenesis at intravenous doses received by patients from residual BPL in inadequately hydrolyzed plasma products. FDA's acceptable daily intake (ADI) framework for pharmaceutical residual solvents (ICH Q3C) would require BPL to be classified in the most restrictive Category 1 (carcinogenic; avoid; permissible daily intake not established) — a category for which the only acceptable answer is analytical confirmation of undetectable residuals. The Surface 3 upward pH attack suppresses the recognition that the pH-5.4 hydrolysis environment has left 42% of the BPL incompletely hydrolyzed, enabling batch release with residual BPL at concentrations that the ICH Q3C framework would prohibit if detected.

Integrating Glyphward into BPL Plasma Virus Inactivation AI Monitoring Pipelines

The following Python snippet demonstrates how to authenticate BPL atmospheric monitor, in-process concentration analyzer, and hydrolysis pH sensor display images against the Glyphward API before passing readings to a pharmaceutical batch-management AI that makes virus inactivation clearance, batch release, and CGMP documentation decisions. A non-clean verdict raises a typed exception triggering: immediate BPL addition halt, batch quarantine pending manual re-verification, OSHA 1910.1013 emergency response activation, and FDA batch record hold.

import asyncio
import hashlib
from enum import StrEnum, auto
from pathlib import Path

import httpx

GLYPHWARD_API = "https://api.glyphward.com/v1/scan"
GLYPHWARD_KEY = "gw_live_..."   # set via env var GLYPHWARD_API_KEY
BPL_GLYPHWARD_THRESHOLD = 46

class BPLContext(StrEnum):
    ATMOSPHERIC_MONITOR      = auto()   # Surface 1 — downward
    INPROCESS_CONCENTRATION  = auto()   # Surface 2 — downward
    HYDROLYSIS_PH            = auto()   # Surface 3 — upward

class AdversarialBPLImageError(RuntimeError):
    def __init__(self, surface: BPLContext, score: int, frame_hash: str):
        super().__init__(
            f"[Glyphward] BPL adversarial pixel on {surface.value}: "
            f"score={score} >= threshold={BPL_GLYPHWARD_THRESHOLD} "
            f"| frame={frame_hash}"
        )
        self.surface = surface
        self.score = score
        self.frame_hash = frame_hash

async def verify_bpl_frame(frame_path: Path, surface: BPLContext) -> dict:
    raw = frame_path.read_bytes()
    frame_hash = hashlib.sha256(raw).hexdigest()
    async with httpx.AsyncClient(timeout=4.0) as client:
        resp = await client.post(
            GLYPHWARD_API,
            headers={"Authorization": f"Bearer {GLYPHWARD_KEY}"},
            files={"image": (frame_path.name, raw, "image/png")},
            data={"context": surface.value, "threshold": BPL_GLYPHWARD_THRESHOLD},
        )
        resp.raise_for_status()
        result = resp.json()
    if result["verdict"] != "clean":
        raise AdversarialBPLImageError(surface, result["score"], frame_hash)
    return {"verdict": result["verdict"], "score": result["score"], "hash": frame_hash}

async def safe_bpl_plasma_monitoring_read(frame_dir: Path) -> list[dict]:
    surfaces = [
        (BPLContext.ATMOSPHERIC_MONITOR,     frame_dir / "bpl_atmospheric.png"),
        (BPLContext.INPROCESS_CONCENTRATION, frame_dir / "bpl_inprocess.png"),
        (BPLContext.HYDROLYSIS_PH,           frame_dir / "hydrolysis_ph.png"),
    ]
    tasks = [verify_bpl_frame(path, ctx) for ctx, path in surfaces]
    return await asyncio.gather(*tasks)

All three verification calls execute concurrently, adding under 80 ms per batch-management monitoring cycle. Glyphward threshold 46 for BPL is the highest threshold in the Glyphward pharmaceutical monitoring portfolio, reflecting: OSHA 1910.1013 specific carcinogen standard — the highest-weight OSHA carcinogen regulatory designation, shared by only 12 other chemicals (including vinyl chloride, acrylonitrile, and ethylene oxide) in the entire US regulatory framework; the dual patient-safety consequence of Surfaces 2 and 3 (blood-borne pathogen transmission + IV carcinogen residual exposure), which introduce blood product safety stakes absent in occupational-only chemical attack scenarios; CERCLA RQ 10 lbs (among the lowest for a pharmaceutical-use compound, reflecting BPL's high toxicological concern weight per unit mass); and the FDA CGMP batch-record falsification consequence that makes each surface failure not merely a safety event but also a regulatory documentation violation under 21 CFR Part 640 with blood product recall implications. SHA-256 frame hashes provide OSHA 1910.1013, FDA 21 CFR Part 640, ICH Q5A viral safety, and ICH Q3C residual solvent audit traceability for every plasma virus inactivation batch management decision in the pharmaceutical AI pipeline.